Intrinsiqq
Annexon, Inc. logo

Annexon, Inc. Insider Trading

ANNX

Compare
Last 12 months

Insiders bought $3.86M and sold 313K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market
+$3.55M
9 buys · 10 sales
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
4 / 5
executives and directors
Last open-market buy
Nov 2026
Nov 19, 2026

Get an email when ANNX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 19
    William H. Carson
    Director · bought 34,000 at $3.58
    122K
    43% of stake
  • Sep 24
    Douglas Love
    President and CEO · bought 26,065 at $3.83
    100K
    7.2% of stake
  • May 28
    Muneer A Satter
    Director · bought 613,497 at $5.41
    $3.32M
    6.3% of stake
  • May 11
    William H. Carson
    Director · bought 8,000 at $5.78
    46K
    11% of stake
  • Apr 10
    William H. Carson
    Director · bought 8,000 at $6.20
    50K
    13% of stake
  • Mar 10
    William H. Carson
    Director · bought 8,000 at $5.67
    45K
    15% of stake
  • Mar 2No plan
    Dean Richard Artis
    EVP & Chief Scientific Officer · sold 5,894 at $5.43
    32K
    3.2% of stake
  • Mar 2No plan
    Ted Yednock
    EVP & Chief Innovation Officer · sold 5,566 at $5.42
    30K
    3.5% of stake
  • Mar 2No plan
    Michael Overdorf
    EVP & Chief Business Officer · sold 4,339 at $5.42
    24K
    2.3% of stake
  • Mar 2No plan
    Jamie Dananberg
    Chief Medical Officer · sold 5,820 at $5.43
    32K
    4.5% of stake
  • Mar 2No plan
    Jennifer Lew
    EVP & Chief Financial Officer · sold 5,565 at $5.42
    30K
    3.2% of stake
  • Feb 18No plan
    Dean Richard Artis
    EVP & Chief Scientific Officer · sold 5,290 at $5.10
    27K
    4.1% of stake
  • Feb 18No plan
    Ted Yednock
    EVP & Chief Innovation Officer · sold 7,857 at $5.11
    40K
    7.5% of stake
  • Feb 18No plan
    Michael Overdorf
    EVP & Chief Business Officer · sold 6,225 at $5.10
    32K
    4.8% of stake
  • Feb 18No plan
    Jamie Dananberg
    Chief Medical Officer · sold 5,290 at $5.10
    27K
    6.7% of stake
  • Feb 18No plan
    Jennifer Lew
    EVP & Chief Financial Officer · sold 7,851 at $5.11
    40K
    6.5% of stake
  • Dec 30, 2025
    William H. Carson
    Director · bought 4,115 at $5.02
    21K
    8.2% of stake
  • Dec 1, 2025
    William H. Carson
    Director · bought 4,115 at $4.47
    18K
    8.9% of stake
  • Dec 1, 2025
    Jung Choi
    Director · bought 33,000 at $4.19
    138K
    New position
  • Nov 20, 2025 – Nov 21, 2025
    Muneer A Satter
    Director · bought 822,613 at avg $4.38
    $3.6M
    9.2% of stake
  • Nov 17, 2025 – Nov 19, 2025
    Muneer A Satter
    Director · bought 1,500,000 at avg $3.37
    $5.05M
    20% of stake
  • Oct 30, 2025
    William H. Carson
    Director · bought 4,115 at $3.17
    13K
    9.8% of stake
  • Sep 30, 2025
    William H. Carson
    Director · bought 4,115 at $3.05
    13K
    11% of stake
  • Sep 2, 2025
    William H. Carson
    Director · bought 4,115 at $2.09
    9K
    12% of stake
  • Jul 30, 2025
    William H. Carson
    Director · bought 4,115 at $2.43
    10K
    14% of stake
  • Jul 14, 2025No plan
    Ted Yednock
    EVP & Chief Innovation Officer · sold 1,116 at $2.58
    3K
    1.1% of stake
  • Jul 14, 2025No plan
    Jennifer Lew
    EVP & Chief Financial Officer · sold 1,117 at $2.58
    3K
    0.9% of stake
  • Jul 14, 2025No plan
    Michael Overdorf
    EVP & Chief Business Officer · sold 853 at $2.61
    2K
    0.6% of stake
  • Jun 30, 2025
    William H. Carson
    Director · bought 4,115 at $2.46
    10K
    16% of stake
  • Feb 18, 2025No plan
    Jamie Dananberg
    Chief Medical Officer · sold 5,521 at $2.96
    16K
    14% of stake
  • Feb 18, 2025No plan
    Dean Richard Artis
    EVP & Chief Scientific Officer · sold 5,515 at $2.97
    16K
    6.2% of stake
  • Feb 18, 2025No plan
    Ted Yednock
    EVP & Chief Innovation Officer · sold 8,345 at $2.91
    24K
    12% of stake
  • Feb 18, 2025No plan
    Michael Overdorf
    EVP & Chief Business Officer · sold 6,618 at $2.95
    20K
    7.1% of stake
  • Feb 18, 2025No plan
    Jennifer Lew
    EVP & Chief Financial Officer · sold 6,912 at $2.92
    20K
    8.2% of stake
  • Feb 13, 2025No plan
    Douglas Love
    President and CEO · sold 5,021 at $2.95
    15K
    1.4% of stake
  • Feb 13, 2025No plan
    Jennifer Lew
    EVP & Chief Financial Officer · sold 1,786 at $2.98
    5K
    2.1% of stake
  • Feb 13, 2025No plan
    Ted Yednock
    EVP & Chief Innovation Officer · sold 1,783 at $2.99
    5K
    2.5% of stake
  • Feb 13, 2025No plan
    Michael Overdorf
    EVP & Chief Business Officer · sold 1,425 at $2.99
    4K
    1.5% of stake
  • Dec 2, 2024
    William H. Carson
    Director · bought 3,200 at $5.33
    17K
    14% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ANNX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ANNX

CompareIntrinsic value
SVRASavara Inc.
$4.26-18.23%10
CYRXCryoport Inc.
$19.05-2.56%13
MRVIMaravai Lifesciences Holdings Inc.
$6.98-2.92%10
AMPHAmphastar Pharmaceuticals Inc.
$28.25+0.50%64
MNKDMannKind Corporation
$3.85-2.53%30
COYACoya Therapeutics Inc.
$2.95-1.01%10
ATOSAtossa Therapeutics Inc
$1.60-8.86%10
XLOXilio Therapeutics, Inc.
$7.56+0.67%50

Held by ETFs

ANNX is in 28 US ETFs. The largest of them, with ANNX's weight in each:

Spot a number that looks wrong? Check it in ANNX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ANNX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.